Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1481 of 5804
-
New combo therapy shows promise for tough-to-treat nose and throat cancer
Disease control CompletedThis study consists of two parts: Part 1 encompasses a safety lead - in phase and an expansion phase. In both phases, subjects with advanced nasopharyngeal carcinoma who have previously failed platinum - based chemotherapy and immune checkpoint inhibitors (such as anti - PD - 1 …
Phase: PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New cocktail of cancer drugs shows promise in early lymphoma trial
Disease control Recruiting nowThis study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab or glofitamab in combination with CELMoDs (CC-220 and/or CC-99282) in participants with B-cell NHL.
Phase: PHASE1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New strategy aims to tame high blood pressure in HIV patients
Disease control CompletedThe Managing Hypertension Among People Living with HIV: An InTegrated Model (MAP-IT) a stepped wedge, cluster-randomized controlled trial to evaluate the effect of practice facilitation (PF) on the integration of a Task-Shifting Strategy for hypertension (HTN) control (TASSH) int…
Phase: NA • Sponsor: Dr. Dike Ojji • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New drug combo targets Hard-to-Treat kidney cancer
Disease control Recruiting nowThe purpose of this study is to evaluate the safety and tolerability of: * casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and * casdatifan monotherapy and casdatifan…
Phase: PHASE1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Promising drug combo targets Hard-to-Treat amyloidosis
Disease control OngoingThe purpose of this study is assess safety, safest dose, and effectiveness of venetoclax in combination with dexamethasone in participants with t(11;14) positive relapsed (comes back) or refractory (did not get better) light chain amyloidosis.
Phase: PHASE1, PHASE2 • Sponsor: Columbia University • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New combo therapy takes on glioblastoma before surgery
Disease control Recruiting nowThis is a single-arm pilot study that will recruit 12 patients with newly diagnosed Glioblastoma, a malignant brain tumor with a poor prognosis. Patients will be treated with fractionated stereotactic radiotherapy (FSRT) for 2 weeks, in addition to two doses of Atezolizumab (Tece…
Phase: EARLY_PHASE1 • Sponsor: Stony Brook University • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New hope for kids with rare swelling disorder: daily pill may stop attacks
Disease control OngoingThe purpose of this study is to evaluate the pharmacokinetics (PK), safety and effectiveness of berotralstat to determine the appropriate weight-based dose for pediatric participants 2 to \< 12 years of age for prophylactic treatment to prevent attacks of hereditary angioedema (H…
Phase: PHASE3 • Sponsor: BioCryst Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New stent aims to open blocked veins and heal leg ulcers
Disease control OngoingThis study is a prospective, multicenter, non-randomized, single-arm study to evaluate the performance, safety, and efficacy of the GORE® VIABAHN® FORTEGRA Venous Stent (formerly known as GORE® VIAFORT Vascular Stent) for treatment of symptomatic inferior vena cava obstruction wi…
Phase: NA • Sponsor: W.L.Gore & Associates • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New pill could ease severe endometriosis pain
Symptom relief CompletedThe purpose of this global Phase 2 study is to determine the efficacy, safety, and tolerability of 3 dose levels of OG-6219 in pre-menopausal women between 18 and 49 years of age (inclusive), who have moderate to severe endometriosis-related pain.
Phase: PHASE2 • Sponsor: Organon and Co • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Ear zap device cuts opioid need after major surgery
Symptom relief CompletedThe NSS-2 BRIDGE® device (NSS stands for Neuro-Stimulation System) is a disposable device that stimulates the branches of cranial nerves and of the superficial cervical plexus innervating the ear. Because the stimulation of the nerves of the ear by the NSS-2 BRIDGE® device (NBD®)…
Phase: NA • Sponsor: Jacques E. Chelly • Aim: Symptom relief
Last updated Jul 26, 2026 00:00 UTC
-
New drug trial hopes to slow muscle damage in kids with DMD
Disease control OngoingThe LYNX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics and biomarkers in children with Duchenne muscular dystrophy including a randomized, double-blind, placebo-controlled part A, followed by an open-label part B.
Phase: PHASE2 • Sponsor: Edgewise Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New stent aims to seal brain aneurysms without surgery
Disease control ENROLLING_BY_INVITATIONThis study is a post-marketing clinical study of the Lattice Flow-Diverting Dense-Mesh Stent. It plans to enroll 280 patients, who will be treated for unruptured intracranial aneurysms using the Lattice Flow-Diverting Dense-Mesh Stent. Patients will be followed up at 12 months af…
Sponsor: Xinjian Yang • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Brain pacemaker tweak may ease Parkinson's without fogging thinking
Symptom relief Recruiting nowDeep brain stimulation (DBS) in the dorsal region of the subthalamic nucleus (STN) is very effective for reducing motor symptoms of Parkinson's disease (PD). Modeling studies suggest that this therapy may result in current spread into the ventral STN, causing altered cognitive pr…
Phase: NA • Sponsor: University of California, Davis • Aim: Symptom relief
Last updated Jun 27, 2026 12:01 UTC
-
Digital sleep coach for teens could boost mental health
Symptom relief CompletedThis study will examine the feasibility, acceptability, and effectiveness of two digital sleep interventions in improving sleep regularity and psychiatric health during a critical period of adolescence.
Phase: NA • Sponsor: Duke University • Aim: Symptom relief
Last updated Jul 12, 2026 00:00 UTC
-
Heart device tested in Real-World AF patients
Disease control OngoingThis post-approval study is designed to provide continued real-world clinical evidence to confirm the safety and long-term effectiveness of atrial fibrillation (AF) radiofrequency (RF) technologies (e.g. TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE)) …
Sponsor: Abbott Medical Devices • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New drug aims to protect dialysis Patients' hearts
Disease control Recruiting nowThis is a two-part, phase 2b and phase 3 combined prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1: Phase 2b is a dose-finding study for CSL300 vs placebo. Part 2: Phase 3 aims to assess the efficacy of CSL300 vs placebo on car…
Phase: PHASE2, PHASE3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Blood test could help kids avoid harmful steroid side effects after transplant
Disease control CompletedThe standard treatment for acute graft-vs-host disease (GVHD) is to suppress the activity of the donor immune cells using steroid medications such as prednisone. Although most GVHD, especially in children, responds well to treatment, sometimes (around 1/3 of the time) there is ei…
Phase: PHASE2 • Sponsor: John Levine • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New heart zapping tech tested for stubborn AFib
Disease control CompletedA prospective, two-arm, multi-center, randomized, open-label, pre-market, First-in-Human clinical study designed to provide safety and performance data regarding the use of the Adagio PFA and PFCA Systems in the treatment of PsAF.
Phase: NA • Sponsor: Adagio Medical • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New hope for PAH: rapid drug therapy aims to reverse heart damage
Disease control OngoingThe primary objective of this study is to assess the effect of early and rapid treprostinil therapy for mean pulmonary artery pressure (mPAP) reduction to improve right ventricular (RV) function and reverse RV remodeling in participants with pulmonary arterial hypertension (PAH).
Phase: PHASE4 • Sponsor: United Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New study follows 400 patients on upadacitinib for ulcerative colitis
Disease control OngoingUlcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).This study will assess how effective upadacitinib is in treating UC. Upadacitinib (RINVOQ) is an approved drug for trea…
Sponsor: AbbVie • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC